2020/01/22 by Helen Marshall, Mark McMillan, Ann P. Koehler +13 · 187 citations
Immunology and Microbiology · Medicine · Social Sciences · #Antibody #Bacteria #Bacterial Infections and Vaccines #Biology #Carriage #Environmental health #Genetics #Group A #Group B #Herd immunity #Immunization #Immunology #Internal medicine #Medicine #Meningococcal disease #Meningococcal vaccine #Neisseria meningitidis #Population #Vaccination #Vaccine Coverage and Hesitancy #Virology #Virology and Viral Diseases
paper · pdf · doi:10.1056/nejmoa1900236
published in New England Journal of Medicine 382(4), 318-327 (Massachusetts Medical Society)
openalex publication_date 2020/01/22 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05
BACKGROUND: The meningococcal group B vaccine 4CMenB is a new, recombinant protein-based vaccine that is licensed to protect against invasive group B meningococcal disease. However, its role in preventing transmission and, therefore, inducing population (herd) protection is uncertain. METHODS: and individual disease-causing genogroups. Risk factors for carriage were assessed at baseline. RESULTS: included later year of schooling (adjusted odds ratio for year 12 vs. year 10, 2.75; 95% CI, 2.03 to 3.73), current upper respiratory tract infection (adjusted odds ratio, 1.35; 95% CI, 1.12 to 1.63), cigarette smoking (adjusted odds ratio, 1.91; 95% CI, 1.29 to 2.83), water-pipe smoking (adjusted odds ratio, 1.82; 95% CI, 1.30 to 2.54), attending pubs or clubs (adjusted odds ratio, 1.54; 95% CI, 1.28 to 1.86), and intimate kissing (adjusted odds ratio, 1.65; 95% CI, 1.33 to 2.05). No vaccine safety concerns were identified. CONCLUSIONS: Among Australian adolescents, the 4CMenB vaccine had no discernible effect on the carriage of disease-causing meningococci, including group B. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT03089086.).